Fennec Pharmaceuticals Management
Management criteria checks 2/4
Fennec Pharmaceuticals' CEO is Jeff Hackman, appointed in Aug 2024, has a tenure of less than a year. total yearly compensation is $1.93M, comprised of 11.7% salary and 88.3% bonuses, including company stock and options. directly owns 0.054% of the company’s shares, worth $119.55K. The average tenure of the management team and the board of directors is 0.7 years and 9.9 years respectively.
Key information
Jeff Hackman
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 11.68% |
| CEO tenure | less than a year |
| CEO ownership | 0.05% |
| Management average tenure | less than a year |
| Board average tenure | 9.9yrs |
Recent management updates
Recent updates
Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price Is Matching Sentiment Around Its Revenues
Apr 24
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results
Mar 13Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Nov 24Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
Oct 04
Jeff Hackman's Leadership And PEDMARK's Launch Promise Robust Revenue Surge
Introduction of PEDMARK and strategic partnerships aim to boost net revenues through expanded patient access and improved distribution.Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Aug 15Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
Jun 02Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children
Sep 20Buying Fennec Pharma Ahead Of September PDUFA For Pedmark
Aug 23Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor
Aug 01Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
Oct 29Fennec Could See Upside If Pedmark Gets Approved
Jul 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$2m | US$225k | -US$436k |
Compensation vs Market: Jeff's total compensation ($USD1.93M) is about average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Insufficient data to compare Jeff's compensation with company performance.
CEO
Jeff Hackman (61 yo)
Mr. Jeffrey S. Hackman, also known as Jeff, is CEO and Director at Fennec Pharmaceuticals Inc. He served as Chairman, President and Chief Executive Officer of Comera Life Sciences Holdings, Inc. from May 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$1.93m | 0.054% $ 119.5k | |
| Chief Financial Officer | 9.5yrs | US$1.76m | 0.54% $ 1.2m | |
| Chief Medical Officer | less than a year | US$727.26k | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Strategy Officer | less than a year | no data | no data | |
| Controller | 9.5yrs | no data | no data | |
| President of Pharstat Inc | no data | no data | no data |
Experienced Management: FENC's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$1.93m | 0.054% $ 119.5k | |
| Independent Director | 13.8yrs | US$148.15k | 0.19% $ 428.7k | |
| Independent Chairman of the Board | 11.1yrs | US$182.06k | 0.77% $ 1.7m | |
| Independent Director | 5.7yrs | US$128.15k | 0% $ 0 | |
| Director | 15.8yrs | US$3.24m | 0.25% $ 559.9k | |
| Independent Director | 8.8yrs | US$143.15k | 0% $ 0 |
Experienced Board: FENC's board of directors are considered experienced (9.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 19:38 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fennec Pharmaceuticals Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Naureen Quibria | Capital One Securities, Inc. |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |